Home › NDC Lookup › Ingredients › Dexamethasone Sodium Phosphate › 70069-0025-10
💉image loading
(from DailyMed)

DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL Injection, Solution — NDC 70069-025-10 (Billing 70069-0025-10)

by Somerset Therapeutics, LLC · 10 VIAL in 1 CARTON / 10 mL in 1 VIAL

This is a package of DEXAMETHASONE SODIUM PHOSPHATE 10 mg/mL Injection, Solution from Somerset Therapeutics, LLC, marketed since Jun 2019 and currently FDA-listed; retail pharmacies pay about $0.5104 per mL (NADAC). It is this product's only package size.

NDC 70069-0025-10
🏷️ FDA NDC (as labeled) 70069-025-10 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⚠ On shortage ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Active FDA shortage. Dexamethasone Sodium Phosphate Injection is currently reported in shortage by the FDA. Available Shortage details →
🚨
Active recall for this product.
Class II · Feb 4, 2026 — Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate. (SOMERSET THERAPEUTICS LLC) · FDA recall D-0398-2026
Lots / codes: Lot #: A240421, Exp 07/31/2026 · reported Mar 25, 2026
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗
⚠️
Other active recalls for Dexamethasone Sodium Phosphate (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 23, 2024 — Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec. (Eugia US LLC) · FDA recall D-0555-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70069-025-10
Product NDC 70069-025
11-digit billing NDC 70069002510
NCPDP billing unit ML — per mL (volume)
RxCUI 309696
UNII AI9376Y64P
UPC 0370069025109, 0370069025017
Application # ANDA211036
SPL Set ID 5a1b0266-90c8-4176-a6b0-c4204d3c604e
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-06-11
Route INTRAMUSCULAR, INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance DEXAMETHASONE SODIUM PHOSPHATE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 22100020202060
GPI class Dexamethasone Sodium Phosphate
GCN Seq No 006776
GCN 27350
HICL code 002888
Ingredient (HICL) Dexamethasone Sodium Phosphate
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P5
Therapeutic class — intermediate (HIC2) Adrenocortical Hormones
HIC3 code P5A
Therapeutic class — specific (HIC3) Glucocorticoids
AHFS code 52:08.08.00
AHFS class Corticosteroids (Eent)
FDB label name DEXAMETHASONE 100 MG/10 ML VL
FDB brand name Dexamethasone Sodium Phosphate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006776
  • GCN: 27350
  • GPI-14 (Medi-Span): 22100020202060
  • HICL (First Databank): 002888
  • AHFS class code: 52:08.08.00
  • RxCUI (RxNorm): 309696
Why two NDCs? The FDA registers this code as 70069-025-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70069-0025-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DEXAMETHASONE 100 MG/10 ML VL Ingredient Dexamethasone Sodium Phosphate
📖 What it is MedlinePlus · NLM

Dexamethasone injection is used to treat severe allergic reactions. It is used in the management of certain types of edema (fluid retention and swelling; excess fluid held in body tissues,) gastrointestinal disease, and certain types of arthritis. Dexamethasone injection is also used for diagnostic testing. Dexamethasone injection is also used to treat certain conditions that affect the blood, skin, eyes, thyroid, kidneys, lungs, and nervous system. It is sometimes used in combination with other medications to treat symptoms of low corticosteroid levels (lack of certain substances that are usu...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It's a steroid that calms inflammation and immune overreaction. Depending on the product, it treats allergic conditions, skin diseases, hormone disorders and eye conditions. Hemady...
  • Follow your prescription label exactly. Tablets and liquid are swallowed, and your prescriber sets the amount based on your condition. Please don't stop suddenly after long use, be...
  • Increased appetite, weight gain, trouble sleeping, mood swings, nausea and fluid retention are common. Call your doctor for signs of infection, black stools, vision changes, or sev...
  • Some medicines interact with it, including certain antifungals, blood thinners, diabetes medicines, aspirin or NSAIDs, and estrogen products. Check with me before adding anything n...
📖 Read our full Dexamethasone guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
8
Nutrient depletion considerations

Dexamethasone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Dexamethasone nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.510 $51.04 / 100 ml
Medicaid paysCMS SDUD · 12 mo $49.23 $4,923.10 / 100 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J1100 $0.085 / J1100 unit —
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.956 $0.502
▼ Down 45% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)70069-025-10
11-digit billing NDC70069-0025-10
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ1100
DescriptorINJECTION, DEXAMETHASONE SODIUM PHOSPHATE, 1MG
Billing units / pkg10 units
How the units are derivedThis package is 10 ML; the HCPCS unit is 1 MG, so one package = 10 billing units.
Medicare Part B spend (2026 (Q1))$404,364 · 455,323 claims · $0.89 per claim (all NDCs under J1100)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70069-0025-10 You're viewing this Main listing 10 VIAL in 1 CARTON / 10 mL in 1 VIAL 2019-06-11 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Dexamethasone Sodium Phosphate 10 mg/mL 63323-0516-10 Fresenius 10 vials $0.510 AP Availability likely —
Dexamethasone Sodium Phosphate 10 mg/mL 67457-0420-10 Mylan 10 vials $0.510 AP Availability likely —
Dexamethasone Sodium Phosphate 10 mg/mL 67457-0483-10 Mylan 10 vials $0.510 AP Availability likely —
Dexamethasone Sodium Phosphate 10 mg/mLthis 70069-0025-10 Somerset 10 vials $0.510 AP Availability likely —
Dexamethasone Sodium Phosphate 10 mg/mL 55150-0304-25 Eugia 25 vials $1.157 AP Availability likely +127%
Dexamethasone Sodium Phosphate 10 mg/mL 72485-0118-25 Armas 25 vials $1.157 AP Availability likely +127%
Dexamethasone Sodium Phosphate 10 mg/mL 63323-0506-16 Fresenius 25 vials $1.157 AP Availability likely +127%
Dexamethasone Sodium Phosphate 10 mg/mL 70069-0021-25 Somerset 25 vials $1.157 AP Availability likely +127%
Dexamethasone Sodium Phosphate 10 mg/mL 00641-0367-25 Hikma 25 vials $1.236 AP Availability likely +142%
Dexamethasone Sodium Phosphate 10 mg/mL 72572-0122-25 Civica, 25 vials $1.236 AP Availability likely +142%
Dexamethasone Sodium Phosphate 10 mg/mL 00404-9842-10 Henry 1 vial — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 51662-1343-01 HF 1 ml — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 51662-1391-01 HF 10 ml — AP FDA listed —
Dexamethasone Sodium Phosphate 100 mg/10mL 51662-1541-01 HF 10 ml — — FDA listed —
Dexamethasone Sodium Phosphate 100 mg/10mL 55150-0305-10 Eugia 10 vials — — FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 55154-5118-05 Cardinal 5 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 70518-0532-01 REMEDYREPACK 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 71872-7090-01 Medical 1 vial — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 71872-7205-01 Medical 1 vial — AP FDA listed —
Dexamethasone Sodium Phosphate 100 mg/10mL 71872-7239-01 Medical 1 vial — — FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 76420-0399-10 Asclemed 10 vials — AP FDA listed —
Dmt Suik 10 mg/mL 76420-0270-01 Asclemed 1 vial — — FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 71872-7091-01 Medical 1 vial — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 76045-0212-10 Fresenius 1 syringe — AP FDA listed —
Dmt Suik 10 mg/mL 80425-0556-01 Advanced 1 vial — — FDA listed —
Dexamethasone sodium phosphate 10 mg/mL 42571-0432-79 Micro 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 80425-0261-01 Advanced 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 70121-1399-05 Amneal 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 85766-0186-25 Sportpharm 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 76045-0109-10 Fresenius 1 syringe — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 85766-0071-01 Sportpharm 1 ml — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 50090-3541-00 A-S 25 vials — AP FDA listed —
Dexamethasone Sodium Phosphate 10 mg/mL 85766-0214-10 Sportpharm 10 vials — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Jun 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 10 mg / 1 mL UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 2968PHW8QP
    A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • 13.5 mg / 1 mL UNII B22547B95K
    A salt derived from citric acid that helps maintain the proper acid-base balance in the medicine. It's used as a buffer to keep the product stable and at the right pH level.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSomerset Therapeutics, LLC
Application holderSOMERSET THERAPEUTICS LLC
FDA applicationANDA211036 (ANDA)
Labeler code70069
First marketedJun 2019
Product typeHuman Prescription Drug
Portfolio184 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage ~2 min read ▾

INDICATIONS AND USAGE A. Intravenous or intramuscular administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders.

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.

Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis.

Hypercalcemia associated with cancer. 2. Rheumatic disorders.

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis.

Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis.

3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus.

Acute rheumatic carditis. 4. Dermatologic diseases.

Pemphigus. Severe erythema multiforme (Stevens-Johnson Syndrome). Exfoliative dermatitis.

Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis.

Mycosis fungoides. 5. Allergic states .

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis.

Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions.

Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6.

Ophthalmic diseases . Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis.

Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis.

Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis.

Allergic corneal marginal ulcers. Keratitis. 7.

Gastrointestinal diseases . To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy).

8. Respiratory diseases . Symptomatic Sarcoidosis.

Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy. Loeffler's syndrome not manageable by other means.

Aspiration pneumonitis. 9. Hematologic disorders .

Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated). Secondary thrombocytopenia in adults.

Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10.

Neoplastic diseases . For palliative management of: Leukemias and lymphomas in adults. Acute leukemic of childhood.

11. Edematous states . To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

12. Nervous system. Acute exacerbations of multiple sclerosis.

13. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy.

Trichinosis with neurologic… [Excerpted — this section continues on DailyMed.]

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION A. Intravenous or intramuscular administration The initial dosage of dexamethasone sodium phosphate injection, USP may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required.

Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended.

Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists. For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery.

Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally.

This may approximate 0.2 mg/kg/24 hours in divided doses. In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4–8 mg dexamethasone every other day for 1 month have been shown to be effective. The initial dosage should be maintained or adjusted until a satisfactory response is noted.

If after a reasonable period of time there is a lack of satisfactory clinical response, dexamethasone sodium phosphate injection, USP should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this later situation it may be necessary to increase the dosage of Dexamethasone sodium phosphate injection, USP for a period of time consistent with the patient's condition.

If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Frequency of injection usually ranges from once every 3 to 5 days to once every 2 to 3 weeks.

Frequent intra-articular injection may cause damage to joint tissue.

⛔ Contraindications 4 words ▾

CONTRAINDICATIONS Systemic fungal infections.

⚠️ Warnings ~2 min read ▾

WARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy.

The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. In patients on corticosteroid therapy subject to any unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including dexamethasone sodium phosphate injection, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens.

Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages Monitor for the development of infection and consider dexamethasone sodium phosphate injection withdrawal or dosage reduction as needed.

Tuberculosis If dexamethasone sodium phosphate injection is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.

Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including dexamethasone sodium phosphate injection. In corticosteroid-treated patients who have not had these diseases or are nonimmune, particular care should be taken to avoid exposure to varicella and measles: If a dexamethasone sodium phosphate injection-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated.

If varicella develops, treatment with antiviral agents may be considered. If a dexamethasone sodium phosphate injection-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including dexamethasone sodium phosphate injection.

Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with dexamethasone sodium phosphate injection. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

Fungal Infections Corticosteroids, including dexamethasone sodium phosphate injection, may exacerbate systemic fungal infections; therefore, avoid dexamethasone sodium phosphate injection use in the presence of such infections unless dexamethasone sodium phosphate injection is needed to control drug reactions. For patients on chronic dexamethasone sodium phosphate injection therapy who develop systemic fungal infections, dexamethasone sodium phosphate injection withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including dexamethasone sodium phosphate injection, may activate latent amebiasis.

Therefore, it is recomme… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions 180 words ▾

ADVERSE REACTIONS Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatological: Impaired wound healing Thin fragile skin Facial erythema Increased sweating May suppress reactions to skin tests Petechiae and ecchymoses Neurological: Convulsions Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Vertigo Headache Ophthalmic: Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Endocrine: Menstrual irregularities Development of cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Metabolic: Negative nitrogen balance due to protein catabolism Miscellaneous: Hyperpigmentation or hypopigmentation Subcutaneous and cutaneous atrophy Sterile abscess Postinjection flare, following intra-articular use Charcot-like arthropathy Itching, burning, tingling in the ano-genital region

🧬 Clinical Pharmacology 55 words ▾

CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

📦 How Supplied / Storage and Handling 83 words ▾

HOW SUPPLIED Dexamethasone Sodium Phosphate Injection, USP (Preserved) 10 mg/mL is clear, colorless solution and is supplied as follows: NDC No. Strength Vial size 70069- 025 -10 100 mg per 10 mL (10 mg per mL) 10 mL vial, packaged in tens. The vial stopper closure is not made with natural rubber latex Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from light. Store container in carton until contents are used. For Product Inquiry call 1-800-417-9175.

📋 Description 135 words ▾

DESCRIPTION Dexamethasone sodium phosphate injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly. Dexamethasone Sodium Phosphate, C 22 H 28 FNa 2 O 8 P, has a molecular weight of 516.41 and chemically is Pregn-4-ene-3, 20-dione, 9-fluoro-11, 17-dihydroxy-16-methyl-21 (phosphonooxy)-, disodium salt, (11β, 16α). It occurs as a white to practically white powder, is exceedingly hygroscopic, is soluble in water and its solutions have a pH between 7.5 and 9.5.

It has the following structural formula: Each mL of Dexamethasone Sodium Phosphate Injection, USP (Preserved) 10 mg/mL contains dexamethasone sodium phosphate, USP equivalent to 10 mg dexamethasone phosphate; 13.5 mg sodium citrate, dihydrate; 10 mg benzyl alcohol; and Water for Injection, q.s. pH adjusted with citric acid or sodium hydroxide, if necessary. pH: 7.0 to

8.5 Image

⚠️ Precautions ~2 min read ▾

PRECAUTIONS Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.

Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed. Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice.

Intra-articular injection of a corticosteroid may produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis.

If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted. Local injection of a steroid into a previously infected joint is to be avoided. Corticosteroids should not be injected into unstable joints.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See Dosage and Administration Section).

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

📄 Package Label / Principal Display Panel 17 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Container label – 10 mL Carton label – 10 mL Container Label Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
40.6K
Units reimbursed last 4 qtrs
43.5K
Gross reimbursed last 4 qtrs
$2.14M
Avg / prescription
$52.79
Avg / unit
$49.2309
Latest quarter Q1 2026
9.9KRx
Medicaid pays / mL
$49.2309
gross reimbursed
vs
NADAC / mL
$0.5104
acquisition cost
=
Spread
+$48.7205
+9546% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
19% FFS 81% MCO
Fee-for-service · 7,566 Rx Managed care · 33,037 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 52 units · 0.7 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 77 units · 1.3 per 100k residents MN Wisconsin: no data reported WI Michigan: 2,492 units · 24.8 per 100k residents MI New York: 689 units · 3.5 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 1,678 units · 39.6 per 100k residents OR Nevada: 4,646 units · 145 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 82 units · 2.6 per 100k residents IA Illinois: no data reported IL Indiana: 410 units · 6.0 per 100k residents IN Ohio: 876 units · 7.4 per 100k residents OH Pennsylvania: 120 units · 0.9 per 100k residents PA New Jersey: 460 units · 5.0 per 100k residents NJ Massachusetts: 2,133 units · 30.5 per 100k residents MA California: 1,696 units · 4.4 per 100k residents CA Utah: 34 units · 1.0 per 100k residents UT Colorado: 1,345 units · 22.9 per 100k residents CO Nebraska: 22 units · 1.1 per 100k residents NE Missouri: 154 units · 2.5 per 100k residents MO Kentucky: 594 units · 13.1 per 100k residents KY West Virginia: no data reported WV Virginia: 1,865 units · 21.4 per 100k residents VA Maryland: 3,502 units · 56.7 per 100k residents MD Connecticut: 75 units · 2.1 per 100k residents CT Rhode Island: no data reported RI Arizona: 5,365 units · 72.2 per 100k residents AZ New Mexico: no data reported NM Kansas: 858 units · 29.2 per 100k residents KS Arkansas: no data reported AR Tennessee: 1,103 units · 15.5 per 100k residents TN North Carolina: 345 units · 3.2 per 100k residents NC South Carolina: 373 units · 6.9 per 100k residents SC Delaware: no data reported DE Oklahoma: 470 units · 11.6 per 100k residents OK Louisiana: 435 units · 9.5 per 100k residents LA Mississippi: 1,951 units · 66.4 per 100k residents MS Alabama: 926 units · 18.1 per 100k residents AL Georgia: 517 units · 4.7 per 100k residents GA D.C.: 682 units · 100 per 100k residents DC Hawaii: no data reported HI Texas: 506 units · 1.7 per 100k residents TX Florida: 7,007 units · 31.0 per 100k residents FL
Units reimbursed · per 100k residents
0.7145
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nevada 145 /100k
2 D.C. 100 /100k
3 Arizona 72.2 /100k
4 Mississippi 66.4 /100k
5 Maryland 56.7 /100k
6 Oregon 39.6 /100k
7 Florida 31.0 /100k
8 Massachusetts 30.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Dexamethasone Sodium Phosphate — the program that covers self-administered drugs. 11 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dexamethasone Sodium Phosphate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$780.5K
Claims incl. refills
22.5K
Beneficiaries
17.3K
Spend / beneficiary
$45.01
Spend / claim
$34.65
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 70069-0024-25 · Somerset 70069-0027-05 · Somerset →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.